Oncolytic parvoviruses. a new approaches for cancer therapy

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk

Volumn , Issue 2, 2012, Pages 42-47

  Loktev, V B ^a,b   Ivan Kina, T Y ^a   Netesov, S V ^a,c   Chumakov, P M ^c,d,e  

^a STATE RESEARCH CENTER OF VIROLOGY AND BIOTECHNOLOGY VECTOR   (Russian Federation)

^b INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^c NOVOSIBIRSK STATE UNIVERSITY   (Russian Federation)

^d ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; Glioma; Oncolytic viruses; Parvoviruses

Indexed keywords

ANTINEOPLASTIC AGENT; NS1 PROTEIN, PARVOVIRUS; ONCOLYTIC VIRUS; VIRUS PROTEIN;

CHEMISTRY; CYTOTOXICITY; FEMALE; GENE VECTOR; GLIOBLASTOMA; H-1 PARVOVIRUS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METHODOLOGY; NEOPLASM; ONCOLYTIC VIROTHERAPY; REVIEW;

ANTINEOPLASTIC AGENTS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENETIC VECTORS; GLIOBLASTOMA; H-1 PARVOVIRUS; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84868311484     PISSN: 08696047     EISSN: 24143545     Source Type: Journal    
DOI: 10.15690/vramn.v67i2.121     Document Type: Article

References (77)

1. Maxwell I.H., Terrell K.L., Maxwell F. Autonomous parvovirus vectors. Methods. 2002; 28 (2): 168-181. (Pubitemid 35341080)
2. Tattersall P. The evolution of parvoviral taxonomy. In The parvoviruses, ed. J.R. Kerr, M.E. Bloom, R.M. Linden et al. Hodder Arnold: London. 2006. P. 5-14.
3. Chow B.D., Esper F.P. The human bocaviruses: a review and discussion of their role in infection. Clin Lab Med. 2009; 29 (4): p. 695-713.
4. Berns K.I., Parvovirus replication. Microbiol Rev. 1990; 54 (3): 316-329.
5. Rommelaere J., Giese N., Cziepluch C., Cornelis J.J. Parvoviruses as anti-cancer agents. In Viral therapy of human cancers. ed. J.G. Sinkovics, J.C. Horvath. Marcel Dekker: New York. 2005. P. 627-675.
6. Rommelaere J., Cornelis J.J. Antineoplastic activity of parvoviruses. J Virol Methods. 1991; 33 (3): 233-251.
7. Spalholz B.A., Tattersall P. Interaction of minute virus of mice with differentiated cells: strain-dependent target cell specificity is mediated by intracellular factors. J Virol. 1983; 46 (3): 937-943. (Pubitemid 13092500)
8. Young N.S. Parvovirus infection and its treatment. Clin Exp Immunol. 1996; 104 (Suppl. 1): 26-30.
9. Deleu L., Pujol A., Faisst S. et al. Activation of promoter P4 of the autonomous parvovirus minute virus of mice at early S phase is required for productive infection. J Virol. 1999; 73 (5): 3877-3885. (Pubitemid 29189831)
10. Di Piazza M., Mader C., Geletneky K. et al. Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. J Virol. 2007; 81 (8): 4186-4198. (Pubitemid 46586913)
11. Nuesch J.P., Rommelaere J. A viral adaptor protein modulating casein kinase II activity induces cytopathic effects in permissive cells. Proc Natl Acad Sei USA. 2007; 104 (30): 12482-12487. (Pubitemid 47206164)
12. Cornelis J.J., Deleu L., Koch U. et al. Parvovirus oncosuppression in The parvoviruses. Hodder Arnold: London. 2006. P. 365-384.
13. Chen Y.Q., de Foresta F., Hertoghs J. et al. Selective killing of simian virus 40-transformed human fibroblasts by parvovirus H-1. Cancer Res. 1986; 46 (7): 3574-3579. (Pubitemid 16096911)
14. Cornelis J.J., Becquart P., Duponchel N. et al. Transformation of human fibroblasts by ionizing radiation, a chemical carcinogen, or simian virus 40 correlates with an increase in susceptibility to the autonomous parvoviruses H-1 virus and minute virus of mice. J Virol. 1988; 62 (5): 1679-1686.
15. Cornelis J.J., Spruyt N., Spegelaere P. et al. Sensitization of transformed rat fibroblasts to killing by parvovirus minute virus of mice correlates with an increase in viral gene expression. J Virol. 1988; 62 (9): 3438-3444.
16. Van Hille B., Duponchel N., Salome N. et al. Limitations to the expression of parvoviral nonstructural proteins may determine the extent of sensitization of EJ-ras-transformed rat cells to minute virus of mice. Virology. 1989; 171 (1): 89-97.
17. Guetta E., Mineberg M., Mousset S. et al. Selective killing of transformed rat cells by minute virus of mice does not require infectious virus production. J Virol. 1990; 64 (1): 458-462. (Pubitemid 20032653)
18. Salome N., van Hille B., Duponchel N. et al. Sensitization of transformed rat cells to parvovirus MVMp is restricted to specific oncogenes. Oncogene. 1990; 5 (1): 123-130.
19. Mousset S., Ouadrhiri Y., Caillet-Fauquet P. et al. The cytotoxicity of the autonomous parvovirus minute virus of mice nonstructural proteins in FR3T3 rat cells depends on oncogene expression. J Virol. 1994; 68 (10): 6446-6453. (Pubitemid 24294894)
20. Van Pachterbeke C., Tuynder M., Cosyn J.P. et al. Parvovirus H-1 inhibits growth of short-term tumor-derived but not normal mammary tissue cultures. Int J Cancer. 1993; 55 (4): 672-677. (Pubitemid 23328958)
21. Herrero Y.C.M., Cornelis J.J., Herold-Mende C. et al. Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. Int J Cancer. 2004; 109 (1): 76-84. (Pubitemid 38160665)
22. Faisst S., Guittard D., Benner A. et al. Dose-dependent regression of HeLa cell-derived tumours in SCID mice after parvovirus H-1 infection. Int J Cancer. 1998; 75 (4): 584-589. (Pubitemid 28094105)
23. Ball-Goodrich L.J., Leland S.E., Johnson E.A. et al. Rat parvovirus type 1: the prototype for a new rodent parvovirus serogroup. J Virol. 1998; 72 (4): 3289-3299. (Pubitemid 28175574)
24. McKisic M.D., Paturzo EX., Smith A.L. Mouse parvovirus infection potentiates rejection of tumor allografts and modulates T-cell effector functions. Transplantation. 1996; 61 (2): 292-299. (Pubitemid 26044546)
25. Lacroix J., Leuchs B., Li J. et al. Parvovirus HI selectively induces cytotoxic effects on human neuroblastoma cells. Int J Cancer. 2010; 127 (5): 1230-1239.
26. Rommelaere J., Cornelis J.J. Autonomous parvoviruses., in Replication-Competent Viruses for Cancer Therapy. Karger: Basel. 2001. P. 100-128.
27. Randall R.E., Goodboum S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol. 2008; 89 (1): 1-47.
28. Rommelaere J., Geletneky K., Angelova A.L. et al. Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev. 2010; 21 (2-3): 185-195.
29. Cotmore S.F., Tattersall P. The autonomously replicating parvoviruses of vertebrates. Adv Virus Res. 1987; 33: 91-174.
30. Niskanen E.A., Ihalainen T.O., Kalliolinna O. et al. Effect of ATP binding and hydrolysis on dynamics of canine parvovirus NS1. J Virol. 2010; 84 (10): 5391-5403.
31. Chen A.Y., Zhang E.Y., Guan W. et al. The small 11 kDa nonstructural protein of human parvovirus B19 plays a key role in inducing apoptosis during B19 virus infection of primary erythroid progenitor cells. Blood. 2010; 115 (5): 1070-1080.
32. Moehler M.H., Zeidler M., Wilsberg V. et al. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum Gene Ther. 2005; 16 (8): 996-1005. (Pubitemid 41153868)
33. Grekova S.P., Aprahamian M., Daeffler L. et al. Interferon gamma improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer. Cancer Biol Ther. 2011; 12 (10): 888-895.
34. Bhat R., Dempe S., Dinsart C. et al. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. Int J Cancer. 2011; 128 (4): 908-919.
35. Raykov Z., Grekova S., Galabov A.S. et al. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model. Oncol Rep. 2007; 17 (6): 1493-1499.
36. Jacoby R.O., Ball-Goodrich L.J., Besselsen D.G. et al. Rodent parvovirus infections. Lab Anim Sci. 1996; 46 (4): 370-380.
37. Hueffer K., Parrish C.R. Parvovirus host range, cell tropism and evolution. Curr Opin Microbiol. 2003; 6 (4): 392-398. (Pubitemid 37075359)
38. Cotmore S.F., Tattersall P. Parvoviral host range and cell entry mechanisms. Adv Virus Res. 2007; 70: 183-232.
39. Geletneky K., Herrero Y.C.M., Rommelaere J. et al. Oncolytic potential of rodent parvoviruses for cancer therapy in humans: A brief review. J Vet Med B Infect Dis Vet Public Health. 20015; 52 (7-8): 327-330.
40. Angelova A.L., Aprahamian M., Balboni G. et al. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies. Mol Ther. 2009; 17 (7): 1164-1172.
41. Angelova A.L., Aprahamian M., Grekova S.P. et al. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res. 2009; 15 (2): 511-519.
42. Moehler M., Blechacz B., Weiskopf N. et al. Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus Hl and derived vectors. Cancer Gene Ther. 2001; 8 (3): 158-167. (Pubitemid 32322255)
43. Dupressoir T., Vanacker J.M., Comelis J.J. et al. Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells. Cancer Res. 1989; 49 (12): 3203-3208. (Pubitemid 19162125)
44. Van Pachterbeke C., Tuynder M., Brandenburger A. et al. Varying sensitivity of human mammary carcinoma cells to the toxic effect of parvovirus H-1. Eur J Cancer. 1997; 33 (10): 1648-1653. (Pubitemid 28123489)
45. Faisst S., Schlehofer J.R., zur Hausen H. Transformation of human cells by oncogenic viruses supports permissiveness for parvovirus H-1 propagation. J Virol. 1989; 63 (5): 2152-2158. (Pubitemid 19107812)
46. Telerman A., Tuynder M., Dupressoir T. et al. A model for tumor suppression using H-1 parvovirus. Proc Natl Acad Sci USA. 1993; 90 (18): 8702-8706. (Pubitemid 23277738)
47. Rayet B., Lopez-Guerrero J.A., Rommelaere J. et al. Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signalling pathway. J Virol. 1998; 72 (11): 8893-8903. (Pubitemid 28471833)
48. Russell S.J., Brandenburger A., Flemming C.L. et al. Transformation- dependent expression of interleukin genes delivered by a recombinant parvovirus. J Virol. 1992; 66 (5): 2821-2828.
49. Ponnazhagan S., Weigel K.A., Raikwar S.P. et al. Recombinant human parvovirus B19 vectors: erythroid cell-specific delivery and expression of transduced genes. J Virol. 1998; 72 (6): 5224-5230. (Pubitemid 28215705)
50. Malerba M., Daeffler L., Rommelaere J. et al. Replicating parvoviruses that target colon cancer cells. J Virol. 2003; 77 (12): 6683-6691. (Pubitemid 36666862)
51. Singh P., Destito G., Schneemann A. et al. Canine parvoviruslike particles, a novel nanomaterial for tumor targeting. J Nanobiotechnology. 2006; 4: 2.
52. Wetzel K., Struyf S., Van Damme J. et al. MCP-3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells. Int J Cancer. 2007; 120 (6): 1364-1371.
53. Enderlin M., Kleinmann E.V., Struyf S. et al. TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. Cancer Gene Ther. 2009; 16 (2): 149-160.
54. Palmer G.A., Tattersall P. Autonomous parvoviruses as gene transfer vehicles in Parvoviruses, from Molecular Biology to Pathology and Therapeutic Uses. Karger: Basel. 2000. P. 178-202.
55. Brandenburger A., Coessens E., El Bakkouri K. et al. Influence of sequence and size of DNA on packaging efficiency of parvovirus MVM-based vectors. Hum Gene Ther. 1999; 10 (7): 1229-1238. (Pubitemid 29231865)
56. Brandenburger A., Velu T. Autonomous parvovirus vectors: preventing the generation of wild-type or replication-competent virus. J Gene Med. 2004; 6 (Suppl. 1): 203-211.
57. Kestler J., Neeb B., Struyf S. et al. cis requirements for the efficient production of recombinant DNA vectors based on autonomous parvoviruses. Hum Gene Ther. 1999; 10 (10): 1619-1632. (Pubitemid 29328206)
58. Haag A., Menten P., Van Damme J. et al. Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice. Hum Gene Ther. 2000; 11 (4): 597-609. (Pubitemid 30134303)
59. Dupont F., Avalosse B., Karim A. et al. Tumor-selective gene transduction and cell killing with an oncotropic autonomous parvovirus-based vector. Gene Ther. 2000; 7 (9): 790-796. (Pubitemid 30255761)
60. Gancberg D., Zeicher M., Bakkus M. et al. Oncoselective transduction of CD80 and CD86 in tumor cell lines using an autonomous recombinant parvovirus. Anticancer Res. 2000; 20 (3A): 1825-1832. (Pubitemid 30628208)
61. Olijslagers S., Dege A.Y., Dinsart C. et al. Potentiation of a recombinant oncolytic parvovirus by expression of Apoptin. Cancer Gene Ther. 2001; 8 (12): 958-965. (Pubitemid 33140314)
62. Wetzel K., Menten P., Opdenakker G. et al. Transduction of human MCP-3 by a parvoviral vector induces leukocyte infiltration and reduces growth of human cervical carcinoma cell xenografts. J Gene Med. 2001; 3 (4): 326-337. (Pubitemid 33691772)
63. Giese N.A., Raykov Z., DeMartino L. et al. Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther. 2002; 9 (5): 432-442. (Pubitemid 34438585)
64. Palmer G.A., Brogdon J.L., Constant S.L. et al. A nonproliferating parvovirus vaccine vector elicits sustained, protective humoral immunity following a single intravenous or intranasal inoculation. J Virol. 2004; 78 (3): 1101-1108. (Pubitemid 38095820)
65. Cornelis J.J., Salome N., Dinsart C. et al. Vectors based on autonomous parvoviruses: novel tools to treat cancer? J Gene Med. 2004; 6 (Suppl. 1): 193-202.
66. Kimsey RB., Engers H.D., Hirt B. et al. Pathogenicity of fibroblastand lymphocyte-specific variants of minute virus of mice. J Virol. 1986; 59(1): 8-13. (Pubitemid 16062490)
67. Dupont F., Karim A., Dumon J.C. et al. A novel MVMp-based vector system specifically designed to reduce the risk of replication competent virus generation by homologous recombination. Gene Ther. 2001; 8 (12): 921-929.
68. El Bakkouri K., Servais C., Clement N. et al. In vivo anti-tumour activity of recombinant MVM parvoviral vectors carrying the human interleukin-2 cDNA. J Gene Med. 2005; 7 (2): 189-197. (Pubitemid 40348023)
69. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006; 5 (6): 471-484. (Pubitemid 44136959)
70. Ashkar A.A., Rosenthal K.L. Toll-like receptor 9, CpG DNA and innate immunity. Curr Mol Med. 2002; 2 (6): 545-556. (Pubitemid 34982187)
71. Dalpke A., Zimmermann S., Heeg K. Immunopharmacology of CpG DNA. Biol Chem. 2002; 383 (10): 1491-1500. (Pubitemid 35282970)
72. Davila E., Velez M.G., Heppelmann C.J. et al. Creating space: an antigen-independent, CpG-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartment. Blood. 2002; 100 (7): 2537-2545.
73. Raykov Z., Grekova S., Leuchs B. et al. Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity. Int J Cancer. 2008; 122 (12): 2880-2884. (Pubitemid 351631394)
74. Young S.M., McCarty J.D.M., Degtyareva N. et al. Roles of adenoassociated virus Rep protein and human chromosome 19 in sitespecific recombination. J Virol. 2000; 74 (9): 3953-3966. (Pubitemid 30214400)
75. Park K., Kim W.J., Cho Y.H. et al. Cancer gene therapy using adeno-associated virus vectors. Front Biosci. 2008; 13: 2653-2659. (Pubitemid 351611602)
76. Ni T.H., McDonald W.F., Zolotukhin I. et al. Cellular proteins required for adeno-associated virus DNA replication in the absence of adenovirus coinfection. J Virol. 1998; 72 (4): 2777-2787. (Pubitemid 28175514)
77. Herzog R.W., Cao O., Srivastava A. Two decades of clinical gene therapy - success is finally mounting. Discov Med. 2010; 9(45): 105-111.